Systemic Treatment for Adults with Synovial Sarcoma.
Loading...
Embargo End Date
ICR Authors
Authors
Desar, IME
Fleuren, EDG
van der Graaf, WTA
Fleuren, EDG
van der Graaf, WTA
Document Type
Journal Article
Date
2018-03-07
Date Accepted
Abstract
Opinion statement Synovial sarcoma (SS) is a rare, yet highly malignant, type of soft tissue sarcoma (STS), for which survival has not improved significantly during the past years. In this review, we focus on systemic treatment in adults. Compared to other STS, SS are relatively chemosensitive. Ifosfamide and ifosfamide combinations are active in different lines of treatment. In high-risk extremity and chest wall STS, neoadjuvant doxorubicin and ifosfamide has shown as much activity as high-dose ifosfamide. There are indications that combination chemotherapy with doxorubicin and ifosfamide in this setting improves outcome. In the first-line metastatic setting, combination treatment with doxorubicin and ifosfamide is a preferred option in fit patients, while in other patients, sequential doxorubicin and ifosfamide can be considered. In second and later lines, pazopanib and trabectedin have shown activity. Many new approaches to treat metastatic SS are currently under investigation, both preclinical as well as clinical, including other receptor tyrosine kinase inhibitors, epigenetic modulators, compounds interfering with DNA damage response (DDR), and immunotherapy.
Citation
Current treatment options in oncology, 2018, 19 (2), pp. 13 - ?
Source Title
Publisher
ISSN
1527-2729
eISSN
1534-6277
Collections
Research Team
Clinical and Translational Sarcoma